樂
樂觀
樂觀 · 25%KLRS
$2.74
情境價格
$2.420
+0.061 (+2.54%)收盤時
Loading chart…
- 最高
- 2.660
- 開盤
- 2.360
- 成交量加權均價
- 2.47
- 成交量
- 201.00K
- 市值
- —
- 最低
- 2.340
- 成交金額
- 497.14K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
AI 分析 of Kalaris Therapeutics Inc (KLRS)
持有Kalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
估值指標
Kalaris Therapeutics Inc（KLRS）目前預期本益比為 0.00，5 年平均預期本益比為 -1.86。
Alphio AI 對 KLRS 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 KLRS 的大戶
事件時間軸
資訊
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
5.007-20seekingalphaKalaris Therapeutics Appoints New CFO
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in Retinal Diseases
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in AMD
- 2.007-17Newsfilter
Kalaris Reports Positive Data for TH103 in AMD Treatment
KLRS 常見問題 —— 由 Alphio AI 解答
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO). It operates in the Healthcare sector.
Kalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。